MEI Pharma, Inc.
3611 Valley Centre Drive, Suite #500
About MEI Pharma, Inc.
MEI Pharma is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's portfolio of drug candidates includes Pracinostat, a potential best-in-class, oral HDAC inhibitor currently in Phase II clinical studies for advanced hematologic diseases. The Company is also developing ME-344, a novel mitochondrial inhibitor that has shown evidence of clinical activity in refractory solid tumors, and ME-401 (formerly PWT143), a highly selective, oral PI3K delta inhibitor. For more information, please visit www.meipharma.com.
CEO: Daniel Gold, PhD
Please click here for clinical trial information.
Please click here for Mei Pharma job opportunities.
296 articles with MEI Pharma, Inc.
Marshall Edwards, Inc. Reaches Agreement in Principle to Acquire Intellectual Property Portfolio From Novogen Limited
Marshall Edwards, Inc. Announces Additional Management Changes With Appointment of New Chief Financial Officer Daniel P. Gold, Ph.D.
Marshall Edwards, Inc. Announces Final Results From Halted Phase 3 Clinical Trial of Phenoxodiol; Drug Does Not Improve Overall Survival Rate of Women with Ovarian Cancer
Report on Phase II Clinical Study of Marshall Edwards, Inc.'s Phenoxodiol in Prostate Cancer to Be Presented at American Society of Clinical Oncology
Marshall Edwards, Inc. Announces Stockholder Approval and Implementation of 1:10 Reverse Stock Split
Marshall Edwards, Inc.'s Action Intended to Regain Compliance With Nasdaq Share Price Rule, Benefit Shareholders
Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo